COCP Cocrystal Pharma Inc

Price (delayed)

$1.055

Market cap

$14.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$11.11M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 10

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. ...

Highlights
Cocrystal Pharma's EPS has soared by 54% YoY and by 6% from the previous quarter
Cocrystal Pharma's net income has increased by 44% YoY
The company's equity fell by 44% YoY and by 35% QoQ
The company's quick ratio fell by 40% YoY and by 32% QoQ

Key stats

What are the main financial stats of COCP

COCP stock price

How has the Cocrystal Pharma stock price performed over time
Intraday
-0.47%
1 week
-6.64%
1 month
-19.47%
1 year
-36.08%
YTD
7.76%
QTD
4.46%

Financial performance

How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.26M
Net income
-$8.83M
Gross margin
N/A
Net margin
N/A
Cocrystal Pharma's net income has increased by 44% YoY
The operating income has grown by 42% YoY but it has contracted by 2.7% from the previous quarter

Price vs fundamentals

How does COCP's price correlate with its fundamentals

Growth

What is Cocrystal Pharma's growth rate over time

Valuation

What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
3.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has soared by 54% YoY and by 6% from the previous quarter
The stock's P/B is 173% above its 5-year quarterly average of 1.3 and 42% above its last 4 quarters average of 2.5
The company's equity fell by 44% YoY and by 35% QoQ

Efficiency

How efficient is Cocrystal Pharma business performance
COCP's return on invested capital is up by 32% year-on-year but it is down by 17% since the previous quarter
Cocrystal Pharma's ROE has decreased by 14% from the previous quarter and by 11% YoY
The ROA has contracted by 9% from the previous quarter but it has grown by 4.4% YoY

Dividends

What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COCP.

Financial health

How did Cocrystal Pharma financials performed over time
The total assets is 124% more than the total liabilities
The company's current ratio fell by 42% YoY and by 28% QoQ
The company's quick ratio fell by 40% YoY and by 32% QoQ
The debt is 65% less than the equity
COCP's debt to equity is up by 46% QoQ and by 46% YoY
The company's equity fell by 44% YoY and by 35% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.